Endometriosis is a chronic, estrogen-dependent gynecological disorder affecting approximately 10% of women worldwide that can cause pelvic pain, lead to infertility, and impair quality of life. Whether the condition elevates …
Endometriosis is linked to an increased risk of epithelial ovarian cancer (EOC), especially clear cell and endometrioid subtypes. The extent and prognostic significance of this link are still not fully …
To evaluate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists versus placebo for treatment of endometriosis-associated pain and to compare individual antagonists indirectly for dysmenorrhea and non-menstrual pelvic pain.
Per- and polyfluoroalkyl substances (PFASs) are persistent endocrine-disrupting chemicals implicated in reproductive dysfunction. Epidemiologic evidence examining their association with endometriosis remains inconsistent. Thus, we conducted a PRISMA-compliant systematic review and …
Endometriosis, PCOS, adenomyosis, and dysmenorrhea are major illnesses. Hormonal as well as non-hormonal treatments were evaluated for COCs, progestins, GnRH analogues, LNG-IUS, relugolix, and adjunctive therapies. These treatments resulted in …
To evaluate the effect of endometriosis medical therapies on bone mineral density (BMD).
To assess whether high-dose folic acid supplementation (4-5 mg/day), initiated before conception, reduces the risk of miscarriage and improves pregnancy rates compared to standard-dose supplementation (0.4 mg/day).
Dysmenorrhea is a debilitating symptom in patients with endometriosis, contributing significantly to disease burden. While the relationship between body mass index (BMI) and dysmenorrhea in these patients is unclear, emerging …